View in EDS

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Saved in:
Bibliographic Details
Title: A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.
Authors: Ku G; Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, New York., Shen L; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China., Dayyani F; University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California., Kratz J; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin., Liang X; Hubei Cancer Hospital, Wuhan, China., Liu F; The First Hospital of China Medical University, Shenyang, China., Wang Z; The First Hospital of China Medical University, Shenyang, China., Feller L; Horizon BioAdvance, Lafayette, Indiana., Girda E; Rutgers Cancer Institute, New Brunswick, New Jersey., Pan H; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China., Kim S; University of Colorado Cancer Center, Aurora, Colorado., Deng Y; The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Deng T; Tianjin Cancer Hospital, Tianjin, China., Liu T; Zhongshan Hospital, Fudan University, Shanghai, China., Powderly J; Carolina BioOncology Institute, Huntersville, North Carolina., Spencer K; Perlmutter Cancer Center of NYU Langone Health & NYU Grossman School of Medicine, New York, New York., Schneider R; Mary Crowley Cancer Research Center, Dallas, Texas., Berlin J; Vanderbilt University Medical Center, Nashville, Tennessee., Xu CC; I-Mab Biopharma, Rockville, Maryland., Ahlers CM; I-Mab Biopharma, Rockville, Maryland., Liu X; I-Mab Biopharma, Rockville, Maryland., Chung JK; I-Mab Biopharma, Rockville, Maryland., Sabbatini P; I-Mab Biopharma, Rockville, Maryland., Park J; ABL Bio Inc., Seongnam, Republic of Korea., Lim Y; ABL Bio Inc., Seongnam, Republic of Korea., Jeon J; ABL Bio Inc., Seongnam, Republic of Korea., Meng Y; TJ Biopharma, Hangzhou, China., Klempner SJ; Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Dec 01; Vol. 31 (23), pp. 4944-4952.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40586719
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ku+G%22">Ku G</searchLink>; Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, New York.<br /><searchLink fieldCode="AU" term="%22Shen+L%22">Shen L</searchLink>; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Dayyani+F%22">Dayyani F</searchLink>; University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California.<br /><searchLink fieldCode="AU" term="%22Kratz+J%22">Kratz J</searchLink>; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.<br /><searchLink fieldCode="AU" term="%22Liang+X%22">Liang X</searchLink>; Hubei Cancer Hospital, Wuhan, China.<br /><searchLink fieldCode="AU" term="%22Liu+F%22">Liu F</searchLink>; The First Hospital of China Medical University, Shenyang, China.<br /><searchLink fieldCode="AU" term="%22Wang+Z%22">Wang Z</searchLink>; The First Hospital of China Medical University, Shenyang, China.<br /><searchLink fieldCode="AU" term="%22Feller+L%22">Feller L</searchLink>; Horizon BioAdvance, Lafayette, Indiana.<br /><searchLink fieldCode="AU" term="%22Girda+E%22">Girda E</searchLink>; Rutgers Cancer Institute, New Brunswick, New Jersey.<br /><searchLink fieldCode="AU" term="%22Pan+H%22">Pan H</searchLink>; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.<br /><searchLink fieldCode="AU" term="%22Kim+S%22">Kim S</searchLink>; University of Colorado Cancer Center, Aurora, Colorado.<br /><searchLink fieldCode="AU" term="%22Deng+Y%22">Deng Y</searchLink>; The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Deng+T%22">Deng T</searchLink>; Tianjin Cancer Hospital, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Liu+T%22">Liu T</searchLink>; Zhongshan Hospital, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Powderly+J%22">Powderly J</searchLink>; Carolina BioOncology Institute, Huntersville, North Carolina.<br /><searchLink fieldCode="AU" term="%22Spencer+K%22">Spencer K</searchLink>; Perlmutter Cancer Center of NYU Langone Health & NYU Grossman School of Medicine, New York, New York.<br /><searchLink fieldCode="AU" term="%22Schneider+R%22">Schneider R</searchLink>; Mary Crowley Cancer Research Center, Dallas, Texas.<br /><searchLink fieldCode="AU" term="%22Berlin+J%22">Berlin J</searchLink>; Vanderbilt University Medical Center, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Xu+CC%22">Xu CC</searchLink>; I-Mab Biopharma, Rockville, Maryland.<br /><searchLink fieldCode="AU" term="%22Ahlers+CM%22">Ahlers CM</searchLink>; I-Mab Biopharma, Rockville, Maryland.<br /><searchLink fieldCode="AU" term="%22Liu+X%22">Liu X</searchLink>; I-Mab Biopharma, Rockville, Maryland.<br /><searchLink fieldCode="AU" term="%22Chung+JK%22">Chung JK</searchLink>; I-Mab Biopharma, Rockville, Maryland.<br /><searchLink fieldCode="AU" term="%22Sabbatini+P%22">Sabbatini P</searchLink>; I-Mab Biopharma, Rockville, Maryland.<br /><searchLink fieldCode="AU" term="%22Park+J%22">Park J</searchLink>; ABL Bio Inc., Seongnam, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lim+Y%22">Lim Y</searchLink>; ABL Bio Inc., Seongnam, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Jeon+J%22">Jeon J</searchLink>; ABL Bio Inc., Seongnam, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Meng+Y%22">Meng Y</searchLink>; TJ Biopharma, Hangzhou, China.<br /><searchLink fieldCode="AU" term="%22Klempner+SJ%22">Klempner SJ</searchLink>; Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2025 Dec 01; Vol. 31 (23), pp. 4944-4952.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40586719
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-24-4280
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4944
    Titles:
      – TitleFull: A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ku G
      – PersonEntity:
          Name:
            NameFull: Shen L
      – PersonEntity:
          Name:
            NameFull: Dayyani F
      – PersonEntity:
          Name:
            NameFull: Kratz J
      – PersonEntity:
          Name:
            NameFull: Liang X
      – PersonEntity:
          Name:
            NameFull: Liu F
      – PersonEntity:
          Name:
            NameFull: Wang Z
      – PersonEntity:
          Name:
            NameFull: Feller L
      – PersonEntity:
          Name:
            NameFull: Girda E
      – PersonEntity:
          Name:
            NameFull: Pan H
      – PersonEntity:
          Name:
            NameFull: Kim S
      – PersonEntity:
          Name:
            NameFull: Deng Y
      – PersonEntity:
          Name:
            NameFull: Deng T
      – PersonEntity:
          Name:
            NameFull: Liu T
      – PersonEntity:
          Name:
            NameFull: Powderly J
      – PersonEntity:
          Name:
            NameFull: Spencer K
      – PersonEntity:
          Name:
            NameFull: Schneider R
      – PersonEntity:
          Name:
            NameFull: Berlin J
      – PersonEntity:
          Name:
            NameFull: Xu CC
      – PersonEntity:
          Name:
            NameFull: Ahlers CM
      – PersonEntity:
          Name:
            NameFull: Liu X
      – PersonEntity:
          Name:
            NameFull: Chung JK
      – PersonEntity:
          Name:
            NameFull: Sabbatini P
      – PersonEntity:
          Name:
            NameFull: Park J
      – PersonEntity:
          Name:
            NameFull: Lim Y
      – PersonEntity:
          Name:
            NameFull: Jeon J
      – PersonEntity:
          Name:
            NameFull: Meng Y
      – PersonEntity:
          Name:
            NameFull: Klempner SJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 23
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1